Antibody Therapies for Large B-Cell Lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734. doi:10.1182/blood-2010-05-282632
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi:10.1056/NEJMoa011795
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127. doi:10.1200/JCO.2005.05.1003
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391. doi:10.1016/S1470-2045(06)70664-7
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi:10.1200/JCO.2010.28.1618
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808. doi:10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Liu PP, Wang KF, Xia Y, et al. Racial patterns of patients with primary mediastinal large B-cell lymphoma. Med (United States). 2016;95:e4054.
   Google Scholar
• Mary Dwyer N, Hema Sundar M, Fakhri B, et al. NCCN Guidelines Version 1.2021 B-cell lymphomas; 2021.
   Google Scholar
• Vitolo U, Seymour JF, Martelli M, et al. Extranodal Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v91–102. doi:10.1093/annonc/mdw175
   PubMed Web of Science ®Google Scholar
• Gleeson M, Hawkes EA, Cunningham D, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol. 2016;175:668–672. doi:10.1111/bjh.14287
   PubMed Web of Science ®Google Scholar
• Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739–747. doi:10.1111/bjh.14951
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416. doi:10.1056/NEJMoa1214561
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896–1903. doi:10.1200/JCO.2009.26.5942
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381–385. doi:10.3816/CLM.2009.n.074
   PubMedGoogle Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):123–130. doi:10.1093/annonc/mdj030
   PubMed Web of Science ®Google Scholar
• Rieger M, Österborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664–670. doi:10.1093/annonc/mdq418
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015;125(1):33–39. doi:10.1182/blood-2014-05-575092
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–327. doi:10.1016/j.critrevonc.2017.01.009
   PubMed Web of Science ®Google Scholar
• Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res. 2014;59:203–210. doi:10.1007/s12026-014-8542-z
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Ló Pez AJ, White CA, et al. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195. doi:10.1182/blood.V90.6.2188
   PubMed Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34:2210–2231. doi:10.1007/s12325-017-0610-z
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–2919. doi:10.1200/JCO.2012.46.9585
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large b-cell lymphoma. J Clin Oncol. 2017;35:3529–3537. doi:10.1200/JCO.2017.73.3402
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13. doi:10.1186/s13045-020-00900-7
   Web of Science ®Google Scholar
• Merli F, Cavallo F, Salvi F, et al. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. J Geriatr Oncol. 2020;11:37–40. doi:10.1016/j.jgo.2019.06.020
   Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049–8057. doi:10.1158/0008-5472.CAN-08-2268
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non- Hodgkin’s lymphoma. Ann Oncol. 2018;29:1266–1272. doi:10.1093/annonc/mdy056
   PubMed Web of Science ®Google Scholar
• Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115:1204–1213. doi:10.1182/blood-2009-06-229039
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, Phase 2 study. Lancet Oncol. 2020;21:978–988. doi:10.1016/S1470-2045(20)30225-4
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–58. doi:10.1182/blood-2007-01-068056
   PubMed Web of Science ®Google Scholar
• Ciochetto C, Botto B, Passera R, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. Ann Hematol. 2018;97:1619–1626. doi:10.1007/s00277-018-3328-3
   Web of Science ®Google Scholar
• Palanca-Wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a Phase 1 study. Lancet Oncol. 2015;16:704–715. doi:10.1016/S1470-2045(15)70128-2
   PubMed Web of Science ®Google Scholar
• Advani RH, Lebovic D, Chen A, et al. Phase i study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23:1167–1176. doi:10.1158/1078-0432.CCR-16-0772
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6:e254–65. doi:10.1016/S2352-3026(19)30026-2
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20:998–1010. doi:10.1016/S1470-2045(19)30091-9
   PubMed Web of Science ®Google Scholar
• Tilly H, Flowers C, Friedberg JW, et al. POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol. 2019;37(15_suppl):TPS7571. doi:10.1200/JCO.2019.37.15_suppl.TPS7571
   Web of Science ®Google Scholar
• Haioun C, Matasar MJ, Sancho J-M, et al. POLARGO: randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). J Clin Oncol. 2020;38(15_suppl):TPS8070. doi:10.1200/JCO.2020.38.15_suppl.TPS8070
   Web of Science ®Google Scholar
• Polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (PolaR-ICE) as initial salvage therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04665765. Accessed January 24, 2021.
   Google Scholar
• Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094–1105. doi:10.1182/blood-2017-10-813493
   PubMed Web of Science ®Google Scholar
• Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a Phase 1 Study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2020. doi:10.1182/blood.2020007512
   PubMed Web of Science ®Google Scholar
• Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014;20:213–220. doi:10.1158/1078-0432.CCR-13-0580
   PubMed Web of Science ®Google Scholar
• Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012;30:2776–2782. doi:10.1200/JCO.2011.39.4403
   PubMed Web of Science ®Google Scholar
• Trnĕny M, Verhoef G, Dyer MJS, et al. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103:1351–1358. doi:10.3324/haematol.2017.168401
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, de Guibert S, et al. A Phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173:722–730. doi:10.1111/bjh.13992
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328–2330. doi:10.1182/blood-2017-01-764258
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkmate 436 study. J Clin Oncol. 2019;37(33):3081–3089. doi:10.1200/JCO.19.01492
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402. doi:10.1182/blood-2014-09-598763
   PubMed Web of Science ®Google Scholar
• Svoboda J, Bair SM, Landsburg DJ, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020:haematol.2019.238675. doi:10.3324/haematol.2019.238675
   Web of Science ®Google Scholar
• Brentuximab vedotin plus lenalidomide and rituximab for the treatment of relapsed/refractory DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04404283. Accessed January 31, 2021.
   Google Scholar
• Schaper F, van Spriel AB. Antitumor immunity is controlled by tetraspanin proteins. Front Immunol. 2018;9:1185. doi:10.3389/fimmu.2018.01185
   Web of Science ®Google Scholar
• Xu-Monette ZY, Li L, Byrd JC, et al. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016;128:3083–3100. doi:10.1182/blood-2016-05-715094
   Web of Science ®Google Scholar
• Stathis A, Flinn IW, Madan S, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018;36:869–876. doi:10.1007/s10637-018-0570-4
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and tolerability Debio 1562 in combination with rituximab in patients with relapsed and/or refractory DLBCL and other forms of NHL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02564744. Accessed April 10, 2021.
   Google Scholar
• Kroschinsky F, Middeke JM, Janz M, et al. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Invest New Drugs. 2020;38(5):1472–1482. doi:10.1007/s10637-020-00916-3
   Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118:4706–4714. doi:10.1002/cncr.27418
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/JCO.19.00172
   PubMed Web of Science ®Google Scholar
• Pereira DS, Guevara CI, Jin L, et al. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol Cancer Ther. 2015;14:1650–1660. doi:10.1158/1535-7163.MCT-15-0067
   PubMed Web of Science ®Google Scholar
• Robak T, Hellmann A, Kloczko J, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017;176:618–628. doi:10.1111/bjh.14464
   PubMed Web of Science ®Google Scholar
• A study to evaluate safety, tolerability, and pharmacokinetics of escalating doses of ags67e given as monotherapy in subjects with refractory or relapsed lymphoid malignancies - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02175433. Accessed April 10, 2021.
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol. 2016;34:2698–2704. doi:10.1200/JCO.2015.65.9789
   PubMed Web of Science ®Google Scholar
• Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481–489. doi:10.1200/JCO.18.00766
   PubMed Web of Science ®Google Scholar
• Cao Y, Lu W, Sun R, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell non-Hodgkin lymphoma. Front Oncol. 2019;9. doi:10.3389/fonc.2019.00767
   Web of Science ®Google Scholar
• Bond DA, Yildiz V, Wei L, et al. A Phase I study of nivolumab and lenalidomide in relapsed/refractory B cell lymphoma. Blood. 2019;134:4091. doi:10.1182/blood-2019-130539
   Web of Science ®Google Scholar
• Nivolumab with or without varlilumab in treating patients with relapsed or refractory aggressive B-cell lymphomas - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03038672. Accessed February 21, 2021.
   Google Scholar
• Nivolumab/ipilimumab-primed immunotransplant for DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03305445. Accessed February 21, 2021.
   Google Scholar
• Nivolumab and combination chemotherapy in treating participants with diffuse large B-cell lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03704714. Accessed February 21, 2021.
   Google Scholar
• Safety and efficacy of bendamustine, gemcitabine, rituximab, nivolumab (BeGeRN) in patients with r/r DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03259529. Accessed February 21, 2021.
   Google Scholar
• Rituximab, lenalidomide, and nivolumab in treating participants with relapsed or refractory non-germinal center type diffuse large B cell lymphoma or primary central nervous system lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03558750. Accessed February 21, 2021.
   Google Scholar
• A study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02327078. Accessed February 21, 2021.
   Google Scholar
• Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267–270. doi:10.1182/blood-2016-12-758383
   PubMed Web of Science ®Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma. J Clin Oncol. 2019;37(34):3291–3299. doi:10.1200/JCO.19.01389
   PubMed Web of Science ®Google Scholar
• Sheikh S, Kuruvilla J. Pembrolizumab for the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2019;19(11):1119–1126. doi:10.1080/14712598.2019.1659777
   PubMed Web of Science ®Google Scholar
• Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype. Blood. 2019;133(21):2279–2290. doi:10.1182/blood-2018-10-879015
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–4244. doi:10.1158/1078-0432.CCR-10-2660
   PubMed Web of Science ®Google Scholar
• Pembrolizumab for patients with PD-L1 diffuse large B cell lymphoma (DLBCL) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03990961. Accessed February 21, 2021.
   Google Scholar
• Herrera AF, Chen L, Popplewell LL, et al. Preliminary results from a Phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood. 2019;134(Supplement_1):759. doi:10.1182/blood-2019-123163
   Web of Science ®Google Scholar
• Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189:1119–1126. doi:10.1111/bjh.16494
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–1041. doi:10.1182/blood-2016-09-738245
   PubMed Web of Science ®Google Scholar
• Chong EA, Svoboda J, Dwivedy Nasta S, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Blood. 2018;132(Supplement 1):4198. doi:10.1182/blood-2018-99-119502
   Web of Science ®Google Scholar
• Jaeger U, Worel N, McGuirk JP, et al. Portia: a Phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2019;134:5325. doi:10.1182/blood-2019-129120
   Web of Science ®Google Scholar
• Osborne W, Marzolini M, Tholouli E, et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. J Clin Oncol. 2020;38:8001. doi:10.1200/JCO.2020.38.15_suppl.8001
   Web of Science ®Google Scholar
• Frigault MJ, Armand P, Redd RA, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4:122–126. doi:10.1182/bloodadvances.2019000784
   Web of Science ®Google Scholar
• Open label study investigating the safety and efficacy of blinatumomab in combination with pembrolizumab (KEYNOTE-348) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03340766. Accessed February 21, 2021.
   Google Scholar
• Joffe E, Vardhana SA, Kumar A, et al. A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(15_suppl):TPS8072. doi:10.1200/JCO.2020.38.15_suppl.TPS8072
   Web of Science ®Google Scholar
• Younes A, Burke JM, Cheson BD, et al. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-Cell Lymphoma (DLBCL): updated analysis of a Phase I/II Study. Blood. 2019;134:2874. doi:10.1182/blood-2019-123368
   Web of Science ®Google Scholar
• Herbaux C, Casasnovas O, Feugier P, et al. Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): primary analysis of a phase II trial from LYSA. J Clin Oncol. 2020;38(15_suppl):8053. doi:10.1200/JCO.2020.38.15_suppl.8053
   Web of Science ®Google Scholar
• Jacobson CA, Westin JR, Miklos DB, et al. Abstract CT055: phase 1/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). Cancer Res. 2020;(suppl):CT055–CT055.
   Web of Science ®Google Scholar
• Chen RW, Ansell SM, Zinzani PL, et al. Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). J Clin Oncol. 2017;35(15_suppl):TPS7575. doi:10.1200/JCO.2017.35.15_suppl.TPS7575
   Web of Science ®Google Scholar
• Hawkes EA, Chong G, Smith C, et al. Safety and efficacy of induction and maintenance avelumab plus R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL): analysis of the Phase II Avr-CHOP Study. Blood. 2020;136:43–44. doi:10.1182/blood-2020-136024
   Web of Science ®Google Scholar
• Avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy in treating patients with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03440567. Accessed February 21, 2021.
   Google Scholar
• Casulo C, Santoro A, Ando K, et al. Durvalumab (Anti PD-L1) as monotherapy or in combination therapy for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and Follicular Lymphoma (FL): a subgroup analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial. Blood. 2019;134:5320. doi:10.1182/blood-2019-124102
   Web of Science ®Google Scholar
• Nowakowski GS, Willenbacher W, Greil R, et al. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R 2 -CHOP in subjects with previously untreated, high-risk DLBCL. J Clin Oncol. 2019;37:7520. doi:10.1200/JCO.2019.37.15_suppl.7520
   Web of Science ®Google Scholar
• Ribrag V, Lee ST, Rizzieri D, et al. A Phase 1b Study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2020. doi:10.1016/j.clml.2020.12.012
   Web of Science ®Google Scholar
• Herrera AF, Goy A, Mehta A, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2020;95:18–27. doi:10.1002/ajh.25659
   Web of Science ®Google Scholar
• Hirayama AV, Gauthier J, Hay KA, et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Blood. 2018;132:1680. doi:10.1182/blood-2018-99-116745
   Web of Science ®Google Scholar
• Study of durvalumab and lenalidomide in R/R EBV associated DLBCL subtypes, primary CNS and testicular DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03212807. Accessed February 21, 2021.
   Google Scholar
• Powderly JD, Gutierrez M, Wang D, et al. A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas. J Clin Oncol. 2015;33(suppl):TPS3091. doi:10.1200/jco.2015.33.15_suppl.tps3091
   Web of Science ®Google Scholar
• Durvalumab in DLBCL after autologous transplant - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03241017. Accessed February 21, 2021.
   Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24:65–97. doi:10.1146/annurev.immunol.24.021605.090535
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446–6453. doi:10.1158/1078-0432.CCR-09-1339
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Maverakis E, Groshen S, et al. A phase I study of the combination of rituximab and ipilimumab in patients with relapsed/refractory B-cell lymphoma. Clin Cancer Res. 2019;25:7004–7013. doi:10.1158/1078-0432.CCR-19-0438
   Web of Science ®Google Scholar
• Skarbnik AP, Donato ML, Feinman R, et al. Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous stem cell transplantation. Transplant Cell Ther. 2020. doi:10.1016/j.jtct.2020.12.026
   Google Scholar
• Tsai RK, Discher DE. Inhibition of ‘self’ engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180:989–1003. doi:10.1083/jcb.200708043
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–299. doi:10.1016/j.cell.2009.05.045
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379:1711–1721. doi:10.1056/NEJMoa1807315
   PubMed Web of Science ®Google Scholar
• Advani R, Bartlett NL, Smith SM, et al. The first-in-class anti-CD47 antibody HU5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results. Hematol Oncol. 2019;37:89–90. doi:10.1002/hon.57_2629
   Google Scholar
• Ansell SM, Maris M, Lesokhin AM, et al. Phase 1 Study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190–2199. doi:10.1158/1078-0432.CCR-20-3706
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of Patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34:1104–1111. doi:10.1200/JCO.2014.59.1586
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (bite) antibody Blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416. doi:10.1182/blood-2015-06-651380
   PubMed Web of Science ®Google Scholar
• Study to evaluate safety and efficacy of blinatumomab in subjects with relapsed/refractory (R/R) aggressive B-cell NHL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02910063. Accessed February 7, 2021.
   Google Scholar
• Hutchings M, Iacoboni G, Morschhauser F, et al. CD20-Tcb (RG6026), a Novel ‘2:1ʹ format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell Non-Hodgkin’s lymphoma: preliminary results from a Phase I First in Human Trial. Blood. 2018;132:226. doi:10.1182/blood-2018-99-110207
   Web of Science ®Google Scholar
• Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24:4785–4797. doi:10.1158/1078-0432.CCR-18-0455
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Morschhauser F, Iacoboni G, et al. CD20-TCB in relapsed or refractory non-Hodgkin lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation. EHA Libr. 2020;4(suppl):S241.
   Google Scholar
• Morschhauser F, Carlo-Stella C, Offner F, et al. Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell Non-Hodgkin lymphoma: preliminary results from a Phase Ib Trial. Blood. 2019;134:1584. doi:10.1182/blood-2019-123949
   Web of Science ®Google Scholar
• An open-label Phase lB Study of glofitamab and atezolizumab or polatuzumab vedotin in adult patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03533283. Accessed February 7, 2021.
   Google Scholar
• Hutchings M, Gritti G, Sureda A, et al. CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134:2871. doi:10.1182/blood-2019-123978
   Web of Science ®Google Scholar
• A Phase III study evaluating glofitamab in combination with gemcitabine + oxaliplatin vs rituximab in combination with gemcitabine + oxaliplatin in participants with relapsed/refractory diffuse large B-cell lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04408638. Accessed February 7, 2021.
   Google Scholar
• A study of glofitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in participants with non-Hodgkin lymphomas and participants with DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03467373. Accessed February 7, 2021.
   Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6. doi:10.1182/blood-2019-123742
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Olszewski AJ, Munoz J, et al. Mosunetuzumab, a Novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood. 2020;136:37–38. doi:10.1182/blood-2020-136295
   Web of Science ®Google Scholar
• Trial of mosunetuzumab (BTCT4465A) as consolidation therapy in participants with diffuse large B-cell lymphoma following first-line immunochemotherapy and as monotherapy or in combination with polatuzumab vedotin in elderly/unfit participants with previously untreated diffuse large B-cell lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03677154. Accessed February 13, 2021.
   Google Scholar
• Olszewski AJ, Avigdor A, Babu S, et al. Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):43–45. doi:10.1182/blood-2020-136255
   Web of Science ®Google Scholar
• Hutchings M, Lugtenburg P, Mous R, et al. Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): complete dose escalation data and efficacy results from a phase I/II trial. J Clin Oncol. 2020;38:8009. doi:10.1200/JCO.2020.38.15_suppl.8009
   Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Blood. 2020;136:45–46. doi:10.1182/blood-2020-133820
   Web of Science ®Google Scholar
• Safety and efficacy trial of epcoritamab combinations in subjects with B-cell non-Hodgkin lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04663347. Accessed February 7, 2021.
   Google Scholar
• A Phase 3 Trial of epcoritamab in R/R DLBCL - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04628494. Accessed February 7, 2021.
   Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42–43. doi:10.1182/blood-2020-136659
   Web of Science ®Google Scholar
• Assess the anti-tumor activity and safety of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03888105. Accessed February 14, 2021.
   Google Scholar
• Patel K, Michot J-M, Chanan-Khan AA, et al. Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Blood. 2019;134(Supplement_1):4079. doi:10.1182/blood-2019-128564
   Web of Science ®Google Scholar